Patent protection will run out later this decade for many multibillion-dollar medicines and will force their large pharmaceutical makers to find new products and markets. Explore some of the most important trends shaping the largest drugmakers’ market strategies in this Trendline.
|
Access now to discover stories including:
|
-
A new, non-opioid pain drug is here. Getting it to patients could be agony.
-
Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
-
Congress should reconsider breaking up PBMs, experts say
|
|
This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.
|
|
|
|
